Cancer Support Network Hong Kong

Cancer Support Network Hong Kong

Whatsapp

Breast Cancer Immunotherapy Today: What Patients Need to Know About “Immune Checkpoints,” the Latest TNBC Direction, and the Most Important Questions to Ask Your Doctor

From the principles of immune checkpoint inhibitors to clinical evidence for triple-negative breast cancer, this helps patients understand who may benefit and who needs more careful evaluation.

Free cancer support
The Hong Kong Cancer Support Network provides you with comprehensive, free cancer information and professional assistance, ensuring that every patient and family member does not have to face the challenge alone.
Talk to someone now

Why Do Patients Hear “Immunotherapy” Everywhere—Yet Still Worry About Being Misled?

In recent years, immunotherapy has become a major focus in cancer treatment. Breakthroughs in cancers like melanoma have raised hopes that immunotherapy could be a game-changer for many patients. However, in breast cancer, immunotherapy is not suitable for everyone—and it is not a “magic treatment” that automatically means fewer side effects.

What patients truly need is clarity: how immunotherapy works, which breast cancer subtypes have the strongest evidence so far, what combination approaches are changing treatment strategies, and how to talk with doctors about whether they might be in a group more likely to benefit.

The immune system protects the body from external threats such as viruses, bacteria, and fungi. It includes many types of immune cells, including several forms of white blood cells:

  • Neutrophils act as a first-line defense against infections.
  • Macrophages help with engulfing threats and regulating immune responses.
  • Natural killer (NK) cells can attack abnormal cells.
  • T cells are specialized for highly specific recognition—they initiate an attack only after their T-cell receptor (TCR) recognizes a target antigen.

At the same time, the immune system has built-in safety controls to prevent excessive inflammation or autoimmune damage. Regulatory signals can tell T cells to “hit the brakes.” This braking mechanism is called the immune checkpointsystem.

Cancer cells exploit this vulnerability. By expressing signals such as PD-L1, tumors can suppress T-cell activity—effectively preventing immune cells from carrying out their anti-cancer function—allowing the tumor to keep growing.

The Basics: How Immune Cells “Recognize” Threats—and Why They Also “Brake”

Immune Checkpoint Inhibitors: “Releasing the Brake” to Reactivate T Cells

The most established form of immunotherapy today is immune checkpoint inhibitors, commonly targeting PD-1, PD-L1, or CTLA-4. These drugs are typically monoclonal antibodies that block PD-1/PD-L1 pathways, aiming to restore the immune system’s ability—especially T cells—to attack cancer cells.

A key point for patients: immunotherapy responses can be highly polarized. A smaller group of patients may experience strong and durable benefit, while many others may see little to no effect. This is why identifying who is more likely to respond—using factors such as PD-L1 status, immune infiltration in the tumor, and tumor biology—remains central to clinical practice and research.

Why Is Triple-Negative Breast Cancer (TNBC) Most Often Discussed in Immunotherapy?

Triple-negative breast cancer (TNBC) lacks hormone receptors and HER2, leaving fewer standard targeted options. It also carries a higher risk of recurrence and metastasis, making it an urgent area for new therapeutic breakthroughs.

Clinical studies suggest that in some TNBC patients, immunotherapy (for example, pembrolizumab) can produce meaningful tumor shrinkage and more durable responses. However, overall response rates remain limited, highlighting the need for better patient selection and more effective combination strategies.

Patients should remember: “TNBC may be more likely to benefit” does not mean “TNBC will definitely respond.” In many cases, immunotherapy is used together with chemotherapy to improve the chance of response.

HER2-Positive Breast Cancer: Beyond Targeted Therapy—Immune Mechanisms Matter Too

Many patients are familiar with anti-HER2 monoclonal antibodies such as trastuzumab (Herceptin). What is less widely known is that these antibodies may do more than block signaling pathways. They can also trigger ADCC (antibody-dependent cellular cytotoxicity)—a mechanism that activates NK cells to help kill cancer cells bound by the antibody.

Because of this, part of the benefit of HER2 therapy may come from immune-mediated cancer cell killing. When HER2-positive breast cancer develops resistance, researchers have explored adding checkpoint inhibitors to HER2 regimens. Trials such as PANACEA investigated whether “anti-HER2 therapy + immunotherapy” could restore responses in selected patients.

Hormone Receptor–Positive (HR+)/HER2-Negative Breast Cancer: Why Immunotherapy Is More Challenging

HR-positive, HER2-negative breast cancer is the most common subtype. From an immunology perspective, these tumors may be less likely to trigger strong immune reactions, which helps explain why checkpoint inhibitors used alone have shown low response rates in many studies.

Because this subtype affects so many patients, research continues—with a major focus on finding better biomarkers (including more reliable PD-L1 testing approaches or other immune indicators) and discovering combination therapies that can more effectively activate anti-tumor immunity.

A Practical Patient Takeaway: Why “Combination Therapy” Is the Main Research Direction

Since checkpoint inhibitors alone often have modest response rates in breast cancer, many ongoing trials focus on combination strategies, such as:

  • Immunotherapy + chemotherapy (to increase antigen release and improve immune visibility)
  • Immunotherapy + targeted therapy (e.g., HER2-directed approaches)
  • Immunotherapy + hormone therapy or other immune-modulating agents (to enhance immune activity in the tumor microenvironment)

In simple terms, the strategy is to help tumors “show their weaknesses,” reduce immune suppression, and increase the likelihood and durability of response.

Side Effects Should Not Be Underestimated: Immunotherapy Is Not Automatically “Gentler”

Immunotherapy side effects differ from chemotherapy. A major concern is immune-related adverse events, such as:

  • Skin inflammation (dermatitis)
  • Liver inflammation (hepatitis)
  • Lung inflammation (pneumonitis)
  • Intestinal inflammation (colitis)
  • Endocrine dysfunction (e.g., thyroid or pituitary inflammation)

Many are treatable, but some can become serious. Patients should work closely with their care team and seek prompt medical attention if symptoms appear—especially persistent cough, shortness of breath, severe diarrhea, jaundice, or unusual fatigue.

The 5 Most Important Questions Patients Should Ask Their Doctor

  1. What is my breast cancer subtype—TNBC, HER2-positive, or HR-positive/HER2-negative—and where is immunotherapy evidence strongest?
  2. Should I be tested for PD-L1 or other immune biomarkers, and how would the results change treatment decisions?
  3. If immunotherapy is recommended, is it monotherapy or combined with chemo/targeted therapy—and why?
  4. What benefits should I realistically expect (response rate, durability), and what are the key risks?
  5. If the treatment does not work or side effects occur, is there a clear plan for stopping, switching, or managing complications?

Want to know how to choose the most suitable adjuvant therapy for cancer?

Contact our specialists now for professional advice and let us work together to find the best solution for you or your family.
Speak with a specialist immediately

Contact our professional team now

References

Scroll to Top

Review My Order

0

Subtotal

Taxes & shipping calculated at checkout

Checkout